This inventor holds 2 USPTO granted patents. Top assignee: La Jolla Biologics, Inc.. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Christopher T. Leber: Innovator in Cell Culture Technology
Introduction
Christopher T. Leber is a notable inventor based in San Diego, CA, who has made significant contributions to the field of cell culture technology. With a focus on enhancing the efficiency of mammalian cell cultures, he has been awarded 2 patents for his innovative approaches.
Latest Patents
Leber's latest patents revolve around the development of a specialized cell culture medium. These compositions and methods are designed for culturing mammalian cells, incorporating a lithium ion source, fatty acids, and ethanol. The use of this cell culture medium has been shown to improve the production of recombinant polypeptides, such as antibodies, resulting in increased titers and a more favorable glycosylation profile. Additionally, the medium helps to modulate the amounts of high and low molecular weight species, as well as acidic or basic charge variants, compared to traditional media.
Career Highlights
Christopher T. Leber is currently associated with La Jolla Biologics, Inc., where he continues to advance research in biotechnological applications. His work is pivotal in the development of more effective cell culture methods that can significantly impact the production of therapeutic proteins.
Collaborations
Leber collaborates with esteemed colleagues, including Hugh Eugene Murray, IV, and Yiwen Tao. These partnerships enhance the research and development efforts at La Jolla Biologics, Inc., fostering innovation in the field.
Conclusion
Christopher T. Leber's contributions to cell culture technology exemplify the impact of innovative thinking in biotechnology. His patents and ongoing work at La Jolla Biologics, Inc. continue to push the boundaries of what is possible in the production of recombinant proteins.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile